Halliburton Labs has named its newest cohort — and opened applications for the next one. Photo courtesy of Halliburton

Halliburton Labs has doubled the number of clean energy companies that are operating out of its facilities with the addition of its second cohort.

Four companies have been selected for the program, joining four existing member companies of Halliburton Labs, which originally launched last summer. The companies recently announced to the incubator are Alumina Energy, Ionada, Parasanti, and SurgePower Materials.

"We are excited to support and collaborate with this group of early-stage, clean energy companies as they continue their commercialization journey," says Dale Winger, managing director of Halliburton Labs, in a news release. "Each has demonstrated a commitment to accelerating their technologies, and we are eager to help them innovate, develop and scale each company."

The new companies join existing labs members Nanotech Inc, Enexor BioEnergy, Momentum Technologies, and OCO Inc. Nanotech was the first company to join the labs in August 2020, while the other three were added in February.

With the announcement of the new cohort, Halliburton is now accepting applications for its third cohort. Interested companies can apply via the website, and submissions are due by September 3, 2021.

Alumina Energy

Focusing on providing zero-carbon heat and power solutions, Santa Monica, California-based Alumina Energy has created a patented packed bed thermal energy storage technology that can make renewable energy resources a more reliable and cost competitive source of heat and power.

"We are very excited to join Halliburton Labs' cleantech accelerator program and collaborate with their experienced team to advance cleaner, affordable energy," says Sasha Braun Diamont, founder and CEO of Alumina Energy, in the release.

Ionada

Ionada is based in Ontario, Canada, and also has offices in London and Germany. The company has developed an exhaust gas cleaning systems that's designed to reduce emissions from the marine and power generation industries.

"We are receiving tremendous interest from industrial emitters around the world for modular carbon capture systems. Halliburton Labs' engineering, supply chain expertise and global network provide the ideal launching platform for us to scale our business to meet demand," says Edoardo Panziera, CEO of Ionada, in the release.

Parasanti

Headquartered in Austin, Parasanti is a tech company with software and hardware applications geared toward streaming analytics and production machine learning to enhance data analytics,

"Parasanti could not be more honored to be a part of the Halliburton Labs accelerator. With the domain expertise and wealth of knowledge that Haliburton Labs possesses, this accelerator will position Parasanti to leverage our edge hardware and software technologies to enable new artificial intelligence and machine learning solutions in the energy space," says Parasanti co-founders James Hancock and Joshua Seagroves in the release.

SurgePower Materials

San Marcos-based SurgePower Materials has developed a way to produce high-purity graphene from an abundant renewable raw material — a process that will allow for producing concrete, electronics, renewable energy, and batteries in a more sustainable way.

"Our goal is to make SurgePower Materials the key enabler of the forthcoming graphene age with plant-based graphene as an essential component of many new technologies. Our strategic collaboration with Halliburton Labs allows us to leverage their world-class engineering expertise to rapidly scale our production and accelerate the adoption of new graphene-based solutions," says Dr. Michael Opoku, CEO of SurgePower Materials, in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”